Compare Gitlab Inc (GTLB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Sanofi SA — how do they compare? Gitlab Inc trades at $31.81 (market cap $5.54B), while Sanofi SA trades at $44.22 (market cap $103.94B). The key difference: Sanofi SA is far larger — about 18.8× Gitlab Inc's market cap, and Sanofi SA pays a 5.54% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals.
| GTLB | SNY | |
|---|---|---|
Market Cap | $5.54B | $103.94B |
Sector | Technology | Health |
52-Week High | $51.04 | $52.34 |
52-Week Low | $19.42 | $41.33 |
Enterprise Value | $4.29B | $120.43B |
Dividend Yield | — | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab trades at $31.50, down 4.49% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $759.25M in 2025, though net income remained negative at -$6.33M. Recent earnings beats and a strategic position in AI-driven DevSecOps, including a fourth consecutive Gartner Magic Quadrant leadership recognition (Business Wire, 2026-06-17), highlight growth potential despite profitability challenges.
The outlook balances strong revenue growth and market position against high valuation multiples and persistent losses. Analyst consensus targets $32.50, suggesting modest upside, but risks include execution on profitability and competitive pressures in the software sector. Cash flow trends show improvement projected for 2026, yet investor caution is warranted given the elevated P/E ratio of 521.22.
Sanofi (SNY) trades at $44.11, up 2.15% today, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with a P/E of 19.37, net income margin of 15.95%, and consistent earnings beats in recent quarters. Recent FDA approval for Sarclisa's subcutaneous formulation and EU clearance for Cenrifki highlight pipeline progress, while a dividend of $2.42 per share underscores shareholder returns.
Outlook remains positive driven by Dupixent growth and new drug approvals, though risks include EU antitrust probes and competitive pressures. Analysts are mixed with 44% buy ratings, suggesting cautious optimism. The stock presents value with solid cash flow and profitability, but investors should monitor regulatory developments and pipeline execution for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
